Most patients who experience heartburn on GLP-1 therapy have identifiable contributing factors, such as large meal portions, eating close to bedtime, or underlying GERD that may have been previously undiagnosed or inadequately managed
Her low energy levels gave her no desire to eat and when she did, it triggered vomiting
Semaglutide is administered as a once-weekly injection, with most patients following a 7-day interval between doses
She estimates 30 to 40% of them are microdosing either tirzepatide or semaglutide
If youve noticed increased shedding since starting your GLP-1 treatment, youre not aloneand more importantly, this is often preventable with the right approach
To find the proportion of ESI enrollees with a prescription for GLP-1 drugs, outpatient pharmaceutical claims from 2012 to 2022 in the Merative MarketScan Commercial Database were used